Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

VolitionRx

MCap

USD76m

Last close

USD0.81

▲ 0.14 (20.90%)

Canyon Resources

MCap

AUD262m

Last close

AUD0.19

▲ 0.02 (12.12%)

Immix Biopharma

MCap

USD51m

Last close

USD1.82

▲ 0.12 (7.06%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Amoeba – executive interview

Amoeba – executive interview

Amoeba — 1 video in collection

More on this equity

Amoeba is developing biological fungicides for treating diseases such as mildews and rusts, which have a major economic impact on the production globally of a wide range of crops including vines, potatoes, vegetables, cereals and bananas. These novel fungicides are based on the characteristics of the Willaertia magna C2c Maky amoeba.

In this interview, Amoeba CEO and chairman Fabrice Plasson explains why there is so much interest in biological alternatives to conventional crop protection products at present and describes both the progress the company has made so far in commercialising its biofungicides and the additional steps required before Amoeba starts to generate revenues from this technology.

< Previous

Next >

You may also be interested in these:

Industrials

28.08.24

Information Services Corporation – executive interview

Industrials

26.06.24

Electro Optic Systems – Brand video

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free